Current through Register Vol. 35, No. 18, September 24, 2024
A physician shall only be approved as a pharmacist clinician
supervisor after the pharmacist clinician registers with the board by
submitting an application for authority to practice under the supervision of a
licensed physician. The application shall include:
A. the name, address, phone number of the
applicant and his/her proof of current certification as a pharmacist clinician
by the board of pharmacy;
B. the
name, address, and phone number of the supervising physician;
C. a written protocol agreed to and signed by
the pharmacist clinician and the supervising physician that shall include:
(1) a statement identifying the physician
authorized to prescribe dangerous drugs and the pharmacist clinician who is a
party to the guidelines or protocol;
(2) a statement of the types of prescriptive
authority that the pharmacist clinician is authorized to make within his scope
of practice which may include:
(a) a statement
of the types of diseases, dangerous drugs or dangerous drug categories involved
and the type of prescriptive authority authorized in each case; and
(b) a general statement of the procedures,
decision criteria or plan the pharmacist clinician is to follow when exercising
prescriptive authority;
(c) a
statement of the activities the pharmacist clinician is to follow in the course
of exercising prescriptive authority, including documentation of decisions made
and a plan for communication to and consultation with the supervising physician
concerning specific decisions made; documentation may occur on the prescriptive
record, patient profile, patient medical chart or in a separate log book;
and
(d) a statement that describes
appropriate mechanisms for reporting to the physician the pharmacist
clinician's activities in monitoring the patients; and
(e) a statement that describes provisions for
immediate communication or consultation between the pharmacist clinician and
the supervising physician or alternate supervising physician.
D. The pharmacist
clinician may be authorized in the protocol to monitor dangerous drug therapy
as follows:
(1) collecting and reviewing
patient dangerous drug histories;
(2) measuring and reviewing routine patient
vital signs including pulse, temperature, blood pressure and respiration;
and
(3) ordering and evaluating the
results of laboratory tests relating to dangerous drug therapy, including blood
chemistries and cell counts, controlled substance therapy levels, blood, urine,
tissue or other body fluids, culture and sensitivity tests when performed in
accordance with guidelines or protocols applicable to the practice
setting.
E. A pharmacist
clinician may only prescribe controlled substances if he/she:
(1) has obtained a New Mexico controlled
substances registration and a drug enforcement agency registration,
and
(2) prescribes controlled
substances within the parameters of written guidelines or protocols established
under these regulations and Section 3, A. of the Pharmacist Prescriptive
Authority Act.
F. A
pharmacist clinician shall perform only those services that are set forth in
the protocol.
G. Pharmacist
clinicians may prescribe only those drugs described in a board approved
protocol.
H. A physician may
supervise as many pharmacist clinicians as the physician can effectively
supervise and communicate with in the circumstances of their particular
practice setting.
